Onychomycosis: a new emerging infectious disease in childhood population and adolescents. Report on treatment experience with terbinafine and itraconazole in 36 patients

Background  Onychomycosis is a rare disease in children with an estimated prevalence ranging from 0% to 2.6%. Thus far, only limited experience with itraconazole and terbinafine treatment in children with onychomycosis is available in the literature.

[1]  A. Bonifaz,et al.  Dermatophyte onychomycosis in children under 2 years of age: experience of 16 cases , 2007, Journal of the European Academy of Dermatology and Venereology : JEADV.

[2]  B. Sigurgeirsson,et al.  Onychomycosis in Icelandic children , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  J. Roszkiewicz,et al.  Onychomycosis is no longer a rare finding in children , 2006, Mycoses.

[4]  N. Zaias,et al.  The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine. , 2004, Archives of dermatology.

[5]  Aditya K. Gupta,et al.  Onychomycosis in Children: A Brief Overview with Treatment Strategies , 2004, Pediatric dermatology.

[6]  L. Guenther,et al.  Dermatological Manifestations of Down's Syndrome , 2001, Journal of cutaneous medicine and surgery.

[7]  J. del Pozo,et al.  Superficial white onychomycosis in a 3‐year‐old human immunodeficiency virus‐infected child , 2001, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  A. Paller,et al.  Itraconazole pulse therapy for dermatophyte onychomycosis in children. , 2000, Archives of pediatrics & adolescent medicine.

[9]  A. Gupta,et al.  Onychomycosis in children: prevalence and management. , 1998, Pediatric dermatology.

[10]  P. Kullavanijaya,et al.  Onychomycosis in a 2-year-old child successfully treated with oral terbinafine. , 1998, Journal of the American Academy of Dermatology.

[11]  S. Knowles,et al.  Terbinafine therapy may be associated with the development of psoriasis de novo or its exacerbation: four case reports and a review of drug-induced psoriasis. , 1997, Journal of the American Academy of Dermatology.

[12]  B. Elewski,et al.  Onychomycosis in children: prevalence and treatment strategies. , 1997, Journal of the American Academy of Dermatology.

[13]  A. Lucky,et al.  Childhood white superficial onychomycosis caused by Trichophyton rubrum: report of seven cases and review of the literature. , 1997, Journal of the American Academy of Dermatology.

[14]  M. Mori,et al.  Successful Treatment of Onychomycosis with Fluconazole in Two Patients with Hyperimmunoglobulin E Syndrome , 1996, Pediatric dermatology.

[15]  B. Elewski.  Cutaneous mycoses in children , 1996, The British journal of dermatology.

[16]  A. Tosti,et al.  Autosomal dominant pattern of distal subungual onychomycosis caused by Trichophyton rubrum. , 1996, Journal of the American Academy of Dermatology.

[17]  V. Falanga,et al.  UVB therapy decreases the adhesive interaction between peripheral blood mononuclear cells and dermal microvascular endothelium, and regulates the differential expression of CD54, VCAM‐1, and E‐selectin in psoriatic plaques , 1996, The British journal of dermatology.

[18]  T. Jones.  Overview of the use of terbinafine (Lamisil®) in children , 1995, The British journal of dermatology.

[19]  P. Hutchinson,et al.  Novel cycle changes in scalp hair are caused by etretinate therapy , 1995, The British journal of dermatology.

[20]  J. Rosenthal.  Pediatric fungal infections from head to toe: what's new? , 1994, Current opinion in pediatrics.

[21]  R. Hay.  Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. , 1993, Journal of the American Academy of Dermatology.

[22]  M. Boland.  HIV infection in children. , 1990, NAACOG's clinical issues in perinatal and women's health nursing.

[23]  D. Shuttleworth,et al.  Dermatophyte onychomycosis in children , 1989, Clinical and experimental dermatology.